Direct T-cell Presentation by cDC1: The Key Feature for Cancer Vaccine Success?
- PMID: 35802596
- DOI: 10.1158/2326-6066.CIR-22-0473
Direct T-cell Presentation by cDC1: The Key Feature for Cancer Vaccine Success?
Abstract
In this issue of Cancer Immunology Research, Ferris and colleagues demonstrate that type 1 conventional DC (cDC1) vaccines drive tumor rejection through direct antigen presentation, without the need of endogenous cDC1. This suggests that cDC1-based vaccines could represent an optimal strategy to induce antitumor immunity in patients. See related article by Ferris et al., p. 920 (7) .
©2022 American Association for Cancer Research.
Comment in
-
cDC1 Vaccines Drive Tumor Rejection by Direct Presentation Independently of Host cDC1.Cancer Immunol Res. 2022 Aug 3;10(8):920-931. doi: 10.1158/2326-6066.CIR-21-0865. Cancer Immunol Res. 2022. PMID: 35648641 Free PMC article.
Comment on
-
cDC1 Vaccines Drive Tumor Rejection by Direct Presentation Independently of Host cDC1.Cancer Immunol Res. 2022 Aug 3;10(8):920-931. doi: 10.1158/2326-6066.CIR-21-0865. Cancer Immunol Res. 2022. PMID: 35648641 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
